CS logo
small CS logo
Nuovo Ospedale di Prato

Prato, Firenze, Italy
Policlinico a Prato

About Nuovo Ospedale di Prato


  • Top Sponsors
  • Top Collaborators
  • Trials By Phase
  • Recruitment Status
  • Top Conditions
  • Intervention Types
  • Top Intervention Names
  • Trials By Gender
Lead Sponsor
# Trials
Hoffmann-La Roche
10
Italian Sarcoma Group
5
National Cancer Institute, Naples
3
Ospedale Misericordia e Dolce
2
Biotronik SE & Co. KG
1
Byondis B.V.
1
Careggi Hospital
1
ETOP IBCSG Partners Foundation
1
Eli Lilly and Company
1
Fondazione per la Medicina Personalizzata
1
Inhibrx, Inc.
1
Total Rows: 15

Clinical Trials at Nuovo Ospedale di Prato


During the past decade, Nuovo Ospedale di Prato conducted 24 clinical trials. In the 10-year time frame, 24 clinical trials started and 6 clinical trials were completed, i.e. on average, 25% percent of trials that started reached the finish line to date. In the past 5 years, 10 clinical trials started and 3 clinical trials were completed. i.e. 30% of trials that started reached the finish line.
Created with Highcharts 11.1.0TrialsTrials Trend - Last 10 Years3333112255664400000022111100Started TrialsCompleted Trails201520162017201820192020202102468
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
CALC-1 (Cetuximab in Advanced Lung Cancer): Study of 2 Methods of Combining Cetuximab and Gemcitabine in Patients With Advanced Non Small-cell Lung Cancer
2005-11-01
2008-06-01
Completed
100
TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer
2006-12-01
2012-06-01
Completed
760
A Study to Assess All-Cause Mortality and Cardiovascular Morbidity in Participants With Chronic Kidney Disease (CKD) on Dialysis and Those Not on Renal Replacement Therapy Receiving Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) or Reference Erythropoietin Stimulating Agents (ESAs)
2008-12-12
2017-07-27
Completed
2,825
A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer
2011-11-08
2028-11-30
Active, not recruiting
4,804
INOVATYON STUDY -International, Randomized Study in Patients With Ovarian Cancer
2011-06-01
2020-12-17
Completed
617
A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Rituximab (MabThera/Rituxan) in Participants With Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL)
2013-07-31
2019-05-28
Completed
159
Personalized Versus Standard Hydration for Prevention of CI-AKI: a Randomized Trial With Bioimpedance Analysis
2012-09-01
2015-04-01
Completed
296
Phase IIIb Study to Evaluate the Safety and Tolerability of Herceptin SC With Perjeta and Docetaxel in Patients With HER2-positive Advanced Breast Cancer
2015-05-06
2019-02-22
Completed
418

Rows per page:

1–31 of 31

Clinical Trials Sponsors and Collaborators


Out of the total clinical trials conducted in "Nuovo Ospedale di Prato" #1 sponsor was "Hoffmann-La Roche" with 10 trials, followed by "Italian Sarcoma Group" with 5 trials sponsored, "National Cancer Institute, Naples" with 3 trials sponsored, "Ospedale Misericordia e Dolce" with 2 trials sponsored and "Biotronik SE & Co. KG" with 2 trials sponsored. Other sponsors include 5 different institutions and companies that sponsored additional 15 trials in total.
In terms of collaborators to trials, out of the total clinical trials conducted in "Nuovo Ospedale di Prato" #1 collaborator was "PharmaMar" with 4 trials as a collaborator, "Breast International Group" with 2 trials as a collaborator, "Alliance Foundation Trials (AFT)" with 1 trials as a collaborator, "AstraZeneca" with 1 trials as a collaborator and "Averion International Corporation" with 1 trials as a collaborator. Other collaborators include 4 different institutions and companies that were collaborators in the rest 14 trials.
Created with Highcharts 11.1.0Top Leading SponsorsHoffmann-La Roche: 10Hoffmann-La Roche: 10Italian Sarcoma Group: 5Italian Sarcoma Group: 5National CancerInstitute, Naples: 3National CancerInstitute, Naples: 3Ospedale Misericordia e Dolce: 2Ospedale Misericordia e Dolce: 2Biotronik SE & Co. KG: 1Biotronik SE & Co. KG: 1Byondis B.V.: 1Byondis B.V.: 1Careggi Hospital: 1Careggi Hospital: 1ETOP IBCSG PartnersFoundation: 1ETOP IBCSG PartnersFoundation: 1Eli Lilly and Company: 1Eli Lilly and Company: 1Fondazione per laMedicinaPersonalizzata: 1Fondazione per laMedicinaPersonalizzata: 1

Created with Highcharts 11.1.0Top CollaboratorsPharmaMar: 4PharmaMar: 4Breast International Group: 2Breast International Group: 2Alliance FoundationTrials (AFT): 1Alliance FoundationTrials (AFT): 1AstraZeneca: 1AstraZeneca: 1Averion InternationalCorporation: 1Averion InternationalCorporation: 1Frontier Science &Technology ResearchFoundation, Inc.: 1Frontier Science &Technology ResearchFoundation, Inc.: 1Genentech, Inc.: 1Genentech, Inc.: 1Institut JulesBordet/Clinical TrialsSupport Unit (IJB/CTSU):1Institut JulesBordet/Clinical TrialsSupport Unit (IJB/CTSU):1Pfizer: 1Pfizer: 1Princess MargaretHospital, Canada: 1Princess MargaretHospital, Canada: 1

Clinical Trials Conditions at Nuovo Ospedale di Prato


According to Clinical.Site data, the most researched conditions in "Nuovo Ospedale di Prato" are "Acute Kidney Injury" (3 trials), "Breast Cancer" (3 trials), "Advanced Non-Small Cell Lung Cancer" (2 trials), "Metastatic Breast Cancer" (2 trials) and "Advanced Soft Tissue Sarcoma" (1 trials). Many other conditions were trialed in "Nuovo Ospedale di Prato" in a lesser frequency.

Clinical Trials Intervention Types at Nuovo Ospedale di Prato


Most popular intervention types in "Nuovo Ospedale di Prato" are "Drug" (26 trials), "Device" (3 trials), "Other" (3 trials) and "Biological" (1 trials). Other intervention types were less common.
The name of intervention was led by "Atezolizumab" (4 trials), "Placebo" (4 trials), "Trabectedin" (4 trials), "Cyclophosphamide" (3 trials) and "Trastuzumab" (3 trials). Other intervention names were less common.

Clinical Trials Genders at Nuovo Ospedale di Prato


The vast majority of trials in "Nuovo Ospedale di Prato" are 28 trials for "All" genders and 3 trials for "Female" genders.

Clinical Trials Status at Nuovo Ospedale di Prato


Currently, there are NaN active trials in "Nuovo Ospedale di Prato". undefined are not yet recruiting, 8 are recruiting, 10 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 12 completed trials in Nuovo Ospedale di Prato, undefined suspended trials, and undefined terminated clinical trials to date.
Out of the total trials that were conducted in Nuovo Ospedale di Prato, 0 "Phase 1" clinical trials were conducted, 8 "Phase 2" clinical trials and 14 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 2 trials that are defined as “Not Applicable".
Created with Highcharts 11.1.0Trials By PhasePhase 3: 14Phase 3: 14Phase 2: 8Phase 2: 8Not Applicable: 2Not Applicable: 2Phase 4: 2Phase 4: 2

Created with Highcharts 11.1.0Trials StatusCompleted: 12Completed: 12Active, not recruiting: 10Active, not recruiting: 10Recruiting: 8Recruiting: 8Unknown status: 1Unknown status: 1